As mentioned in Section 2, PG, in the form of DMPG, which also inhibits HSPB4-induced TLR2 activation, is already present in an ophthalmic solution used to treat dry eye, indicating a good safety profile in this organ and stability in commercially available topical formulations. This evidence concerns the gene TLR2 and Keratoconjunctivitis sicca.